{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-121446","form_type":"8-K","ticker":"ABPO","cik":"0001893219","company_name":"Abpro Holdings, Inc.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.003459+00:00","generated_at":"2026-05-16T13:15:49.520042+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Abpro submits IND to FDA for phase 1 trial of ABP-102/CT-P72 in HER2+ cancers","bullets":["IND filed for ABP-102/CT-P72, a HER2×CD3 T cell engager targeting HER2-positive solid tumors.","Co-developed with Celltrion; phase 1 start expected in 1H 2026 pending FDA clearance.","Preclinical data presented at AACR 2025 and SITC 2025 showed selective activity in HER2-high tumor models.","First IND submission by Abpro for a solid tumor indication, advancing its immuno-oncology pipeline.","Phase 1 study will evaluate safety, PK, and preliminary efficacy in dose-escalation and expansion cohorts."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-121446","json":"https://secwatch.observer/filing/0001213900-25-121446.json","markdown":"https://secwatch.observer/filing/0001213900-25-121446.md","text":"https://secwatch.observer/filing/0001213900-25-121446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1893219/000121390025121446/0001213900-25-121446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1893219/000121390025121446/ea0269613-8k_abpro.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:15:49.520042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}